Pure Global: Malaysia-Thailand MedTech Shortcut & Its Hidden Traps

This episode unpacks the groundbreaking new regulatory reliance pilot program announced by Malaysia and Thailand. We explore how this collaboration creates an accelerated market access pathway for medical device manufacturers, allowing them to leverage an existing approval in one country to speed up registration in the other. This could significantly reduce time and costs for companies expanding in ASEAN. However, this shortcut is filled with potential pitfalls. We dive into the specific requirements and hidden complexities that could lead to costly delays and rejections if not properly managed. One company's rush to market nearly ended in a year-long setback due to a misunderstanding of local representation and labeling rules under the new pilot. Key questions answered in this episode: - What specific device classes are eligible for the Malaysia-Thailand reliance program? - Is appointing a local Authorized Representative still mandatory for the second country? - How does this pilot program affect labeling and language requirements for your device? - What are the most common documentation mistakes companies make when using this pathway? - Could this pilot be the first step towards a broader ASEAN-wide registration system? - How do you determine if the reliance route is actually faster for your specific product? At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline global market access, helping you navigate complex programs like the Malaysia-Thailand pilot. For a clear strategy, contact us at [email protected] or visit https://pureglobal.com/.